Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch.

Autor: Carrascosa JM; Department of Dermatology, Hospital Universitari Germans Trias i Pujol, IGTP, Universitat Autònoma of Barcelona, Carretera de Canyet, s/n, 08916, Badalona, Barcelona, Spain., Narcisi A; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy., Nomura T; Department of Dermatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan., Ständer S; Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Von-Esmarch-Str. 58, 48149, Münster, Germany., Vestergaard C; Department of Clinical Medicine, The Department of Dermatology and Venereology, Aarhus University Hospital, Palle Juhl-Jensens Boulevard 97, 8200, Århus N, Denmark., Sabatino S; Eli Lilly and Company, Indianapolis, IN, USA., Grond S; Eli Lilly and Company, Indianapolis, IN, USA., Koppelhus U; Eli Lilly and Company, Indianapolis, IN, USA., Elrayes M; Eli Lilly and Company, Indianapolis, IN, USA., Chen YF; Eli Lilly and Company, Indianapolis, IN, USA., Liu C; TigerMed-BDM Inc, Somerset, New Jersey, USA., Wollenberg A; Department of Dermatology and Allergy, Augsburg University Hospital, Augsburg, Germany. wollenberg@lrz.uni-muenchen.de.; Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany. wollenberg@lrz.uni-muenchen.de.; Comprehensive Center for Inflammatory Medicine CCIM, University Hospital Schleswig-Holstein UKSH, Lübeck, Germany. wollenberg@lrz.uni-muenchen.de.
Jazyk: angličtina
Zdroj: Dermatology and therapy [Dermatol Ther (Heidelb)] 2024 Jun; Vol. 14 (6), pp. 1561-1573. Date of Electronic Publication: 2024 May 22.
DOI: 10.1007/s13555-024-01171-7
Abstrakt: Introduction: Patients with moderate-to-severe atopic dermatitis (AD) who are most likely to respond to the Janus kinase (JAK) 1/2 inhibitor baricitinib (BARI) are known to have an impacted body surface area (BSA) ≤ 40% and severe itch (numerical rating scale [NRS] ≥ 7], collectively termed 'BARI itch-dominant' patients. Our objective is to build on our previous work by providing a body region-specific, clinical characterization of the BARI itch-dominant patient at baseline and their response to BARI 4 mg.
Methods: BREEZE-AD7 was a phase 3 trial in adults with moderate-to-severe AD receiving placebo or 2 mg or 4 mg BARI in combination with topical corticosteroids. Assessing only data from BARI itch-dominant patients, we summarized the baseline characteristics and conducted body region-specific analyses on Eczema Area and Severity Index (EASI) data in order to report the response to placebo versus BARI 4 mg within this patient subtype.
Results: BARI 4 mg was highly effective across all body regions; at week 16, 75% improvement was seen in EASI scores (EASI75), and response rates with BARI 4 mg (head/neck, 58.3%; trunk, 69.2%; upper extremities, 61.5%; lower extremities, 87.5%) all exceeded those with placebo (head/neck: 37.5%; trunk, 40.6%; upper extremities, 18.8%; lower extremities, 40.6%) as well as the overall EASI75 rates of the intent-to-treat (ITT) population (BARI, 48.0%; placebo, 23.0%). At baseline, most BARI itch-dominant patients presented with involvement of all regions (mean regional BSA 22.7%-40.3%), highest in the head and neck, mean EASI region scores of 15.7-24.0, and considerably severe sign ratings (mean EASI sub-scores: 1.4-2.3, out of 3), especially for erythema.
Conclusion: BARI itch-dominant patients exhibit AD involvement across all body regions and considerable sign severity, especially erythema. In response to BARI 4 mg, EASI quickly improved across regions, substantially more so in this subtype than in the ITT population.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje